Alzheimer's Matters Blog

Alzheimer's Matters Blog

Alzheimer’s Matters, the official blog of the ADDF, features insights, perspectives and commentary on current topics of interest in Alzheimer’s disease and related drug discovery.

Scientists Prepare for Phase-3 Clinical Trial of Early-Stage Dementia Treatment


Did you know that there are currently no FDA-approved treatments for amnestic mild cognitive impairment (aMCI), the pre-dementia stage of Alzheimer’s disease? It’s a condition that impacts between 10 and 20 percent of all individuals 65 and older, representing an enormous unmet clinical need.

Top 5 Reasons to Attend Our Drug Discovery for Neurodegeneration Conference


What does it take to translate basic science into drugs for neurodegenerative diseases like Alzheimer’s, Multiple Sclerosis and Parkinson’s? We’ll share the answers at our 9th Annual Drug Discovery for Neurodegeneration Conference from March 1-3, 2015 in San Diego, CA.

A Banner Year for Alzheimer’s Drug Discovery


What does success mean for the Alzheimer’s Drug Discovery Foundation? It means advancing drug discovery for Alzheimer’s disease, supporting the best and brightest scientists in the world and ensuring that individuals have the information they need to ensure a life of cognitive vitality.By any of these measures, it’s safe to say that 2014 was our most transformative year yet. 

Will an Erectile Dysfunction Drug Be the Next Treatment for Dementia?


The wire has been buzzing with news that the Alzheimer’s Drug Discovery Foundation (ADDF) and the Alzheimer’s Society UK have teamed up to explore the possibility that a commonly prescribed drug for impotence may benefit patients with dementia. This is the first-ever study researching the use of an erectile dysfunction drug for vascular dementia, a form of dementia that affects an estimated one million Americans and is often seen in combination with Alzheimer’s disease.

Living with Alzheimer’s: Tips for a Happy and Healthy Holiday Season


Family tension. Long-distance travel. Expensive gifts. Extensive preparations. It’s no secret that the holidays can be a stressful time. For families living with Alzheimer’s, that anxiety is often magnified by the trials brought on by an uptick in activities, exposure to unfamiliar places and breaks in routine. We’ve put together a few tips to help you and your loved ones enjoy the holiday season while managing the challenges and changes that come with Alzheimer’s disease.

The $3.3 Billion Case for Venture Philanthropy


Recently, the The New York Times covered the news that the Cystic Fibrosis Foundation (CFF) had received a record-breaking $3.3 billion return on its $150 million investment. Even more impressive: the CFF’s early and continuous investment led to the development of the first FDA-approved drug to treat the root causes of cystic fibrosis, rather than the lung disease’s symptoms. 

3 Reasons We’re Thankful


This year, the Alzheimer’s Drug Discovery Foundation has so many reasons to be thankful. Your support has enabled us to make tremendous progress in our search for an effective treatment, and a cure, for Alzheimer’s disease. Here, we highlight a few of the most exciting research developments.

Dan Gasby: “I’m Fighting to End Alzheimer’s”


Four years ago, I received the shock of a lifetime: my wife of 22 years, B. Smith, was diagnosed with early-onset Alzheimer’s disease. There were signs leading up to B.’s diagnosis—signs we desperately tried to ignore. Always an effortless chef, B. had begun taking a little longer to put our meals together. Ever punctual, B. was beginning to have trouble getting out the door on time.

A Three-Dimensional Model of Alzheimer’s


There's no doubt you've read the news: scientists have successfully modeled some of the key features of Alzheimer’s disease in a dish. The new technology, developed by a team of researchers at Massachusetts General Hospital (MGH) led by Rudolph E. Tanzi, may offer a more accurate, efficient and inexpensive way to screen prospective drugs for Alzheimer’s while also advancing our ability to understand the biological processes that lead to the disease.

What Does the Nobel Discovery Mean for the Treatment of Alzheimer’s Disease?


We’d like to send our congratulations to John O’Keefe, May-Britt Moser and Edvard Moser, recipients of The Nobel Prize in Physiology or Medicine 2014 for their discoveries of “place cells” and “grid cells” in the hippocampus and entorhinal cortex of the brain.  These GPS cells help humans to create a map of our surroundings, allowing us to navigate both new and familiar environments, and provide a space and time context in which new memories can be formed. 

Go to top